WHO adds Gilead's twice-yearly injection to global PrEP guidelines

Kyle LaHucik

Biotech Correspondent

KIGALI, RWANDA — Weeks after the FDA’s watershed approval of Gilead’s twice-yearly HIV prevention injection, the World Health Organization recommended the product …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

WHO adds Gilead's twice-yearly injection to global PrEP guidelines

Kyle LaHucik

Biotech Correspondent

Sign up to read this article for free.

23andMe files for bankruptcy, CEO Wojcicki steps down

Regeneron plans to buy 23andMe for $256M

FDA declines to approve Ultragenyx's Sanfilippo gene therapy, citing manufacturing issues

23andMe's CEO files plan to take company private

FDA chief calls for lower user fees as negotiations begin for eighth round of PDUFA

After long saga, 23andMe's deal with Anne Wojcicki's nonprofit finally closes

WHO adds Gilead­'s twice-year­ly in­jec­tion to glob­al PrEP guide­lines

Kyle LaHucik

Biotech Correspondent

Sign up to read this article for free.

more like this

23andMe files for bank­rupt­cy, CEO Wo­j­ci­c­ki steps down

Re­gen­eron plans to buy 23andMe for $256M

FDA de­clines to ap­prove Ul­tragenyx's San­fil­ip­po gene ther­a­py, cit­ing man­u­fac­tur­ing is­sues

23and­Me's CEO files plan to take com­pa­ny pri­vate

FDA chief calls for low­er user fees as ne­go­ti­a­tions be­gin for eighth round of PDU­FA

Af­ter long saga, 23and­Me's deal with Anne Wo­j­ci­ck­i's non­prof­it fi­nal­ly clos­es

WHO adds Gilead's twice-yearly injection to global PrEP guidelines

23andMe files for bankruptcy, CEO Wojcicki steps down

Regeneron plans to buy 23andMe for $256M

FDA declines to approve Ultragenyx's Sanfilippo gene therapy, citing manufacturing issues

23andMe's CEO files plan to take company private

FDA chief calls for lower user fees as negotiations begin for eighth round of PDUFA

After long saga, 23andMe's deal with Anne Wojcicki's nonprofit finally closes